From discovery to verification: Unlocking miRNA biomarkers with NGS and digital PCR

Advancements in next-generation sequencing (NGS) have transformed transcriptome and small RNA profiling, enabling gene expression studies and the identification of splice variants, isoforms and novel transcripts from challenging samples like liquid biopsies, FFPE tumors and exosomes. This enhances our understanding of molecular mechanisms and aids in identifying RNA variants as potential disease biomarkers.

In this webinar, we will explore a complete workflow for miRNA biomarker discovery and verification using NGS and digital PCR (dPCR).

Learning objectives

Set up for miRNA-seq success: Considerations for sample extraction and library preparation for miRNA-seq projects
Analyzing your data: Bioinformatic pipeline for analysis
dPCR assay design: How to leverage sequencing data to verify and design sensitive miRNA biomarker assays by dPCR
Best practices for sequencing projects: Tips for engaging with sequencing cores

About the speaker

Samuel Rulli, Ph.D., Director, Global Product Management, RNA-seq profiling, NGS assay technologies

QIAGEN

Dr. Samuel Rulli received his PhD in Molecular and Cellular Biology from Tulane University in 2002, studying the gastric proton pump. After his postdoctoral training at Johns Hopkins University and the National Cancer Institute, he joined QIAGEN in 2009. As the Associate Director of Global Product Management for NGS technologies, Samuel has been instrumental in developing gene expression analysis solutions for qPCR and NGS.